CTLT - CTLT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Catalent to Novo Holdings | Benzinga
MONSEY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $63.50 per share in cash for which Catalent, Inc. (NYSE:CTLT) ("Catalent") has agreed to be sold to Novo Holdings.
Notably, Novo Holdings is the controlling shareholder of the Novo Group companies (including Novo Nordisk), and Catalent is one of Novo Nordisk's main manufacturing partners for its popular weight-loss drug Wegovy.
If you remain a Catalent shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/catalent/
Alternatively, you may contact us by phone at 866-833-6245, or ...